News
Podcast: Championing the next generation of life sciences talent, a NIHR perspective
1+ hour, 37+ min ago (144+ words) Clinical Trials Arena With so much innovation happening within the life sciences sector, now is arguably the perfect time for new faces to join the industry. During the conversation, Koufali explores the common stereotypes and misconceptions around careers in life…...
ASCO26: Rev Med's daraxonrasib presents a turning point for pancreatic cancer
1+ week, 2+ day ago (464+ words) Clinical Trials Arena At the 2026 American Society of Clinical Oncology (ASCO) annual congress, topline data from the Phase III RASolute 302 was presented at the plenary session. At an 8. 5-month follow-up all primary and secondary endpoints were met. Previously treated metastatic…...
ASCO26: BMS and J&J debut shining multiple myeloma data
1+ week, 3+ day ago (577+ words) Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026. Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting. Data was announced by both Bristol…...
Orion Pharma reports Phase I data from TEADES trial for solid tumours
1+ week, 3+ day ago (263+ words) Orion Pharma has reported data from the Phase I segment of its ongoing Phase I/II TEADES trial, assessing ODM-212 in patients with advanced solid tumours. The results showed ODM-212 was well tolerated, with no dose-limiting toxicities and no maximum…...
ASCO26: Astra Zeneca's light chain amyloidosis shows subgroup benefit after Phase III trial
1+ week, 6+ day ago (341+ words) The data on the kappa AL amyloidosis group treated with anselamimab was presented by Astra Zeneca at ASCO 2026. Astra Zeneca's investigational anti-fibril therapy, anselamimab, did not meet its primary endpoint in a Phase III trial in the overall light chain…...
Concert AI enhances Cancer Lin Q Suite for oncology trials
1+ week, 6+ day ago (273+ words) These updates aim to support oncologists and care teams in processing structured and unstructured data, delivering timely intelligence for trial enrolment and treatment decisions within existing workflows. Cancer Lin Q Suite uses AI to convert unstructured data into actionable insights…...
Clinical trial experts cite trust and regulatory uncertainty as AI barriers
1+ week, 6+ day ago (228+ words) The survey was conducted by the Pistoia Alliance at the Clinical Trials Technology Congress (CTTC) in London. Half of clinical trial experts asked in a recent survey cited trust and regulatory uncertainty as the major barriers to artificial intelligence (AI)…...
Lilly reports positive interim results from Heart-2 trial of VERVE-102
2+ week, 2+ day ago (247+ words) Eli Lilly and Company has reported positive interim results from the ongoing Phase Ib Heart-2 clinical trial of VERVE-102, an investigational therapy intended as a one-time treatment for hypercholesterolaemia. A single dose of VERVE-102, administered intravenously, showed dose-dependent mean reductions…...
Q&A: How 3 PLs are navigating the latest pharma trends
2+ week, 6+ day ago (654+ words) Clinical Trials Arena In Association with Cencora Pharmaceutical third-party logistics (3 PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same time, rising demand for temperature-sensitive biologics and increasingly strict regulations necessitates 3 PLs to…...
First patient dosed in Merck's Phase III PROCEADE-CRC-03 trial for m CRC
2+ week, 6+ day ago (337+ words) The trial assesses Precem-Tc T efficacy and safety alone or with bevacizumab in m CRC patients after previous therapies. The trial is being conducted across nearly 165 sites in 20 countries and aims to enrol around 1, 020 m CRC patients. PROCEADE-CRC-03 is designed…...